Johannes Winkler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5878610/publications.pdf

Version: 2024-02-01

62 papers	2,281 citations	279778 23 h-index	223791 46 g-index
66 all docs	66 docs citations	66 times ranked	3924 citing authors

#	Article	IF	Citations
1	Cell-Based HIF1Î± Gene Therapy Reduces Myocardial Scar and Enhances Angiopoietic Proteome, Transcriptomic and miRNA Expression in Experimental Chronic Left Ventricular Dysfunction. Frontiers in Bioengineering and Biotechnology, 2022, 10, .	4.1	1
2	CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. European Heart Journal, 2021, 42, 192-201.	2.2	70
3	Novel Identified Circular Transcript of RCAN2, circ-RCAN2, Shows Deviated Expression Pattern in Pig Reperfused Infarcted Myocardium and Hypoxic Porcine Cardiac Progenitor Cells In Vitro. International Journal of Molecular Sciences, 2021, 22, 1390.	4.1	4
4	Therapeutic strategies for modulating epigenetic mechanisms in cardiovascular disease. , 2021, , 349-373.		0
5	Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance. Cardiovascular Research, 2020, 116, 970-982.	3.8	32
6	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	4.1	9
7	Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine. Biomolecules, 2020, 10, 1180.	4.0	23
8	Comparative Effect of MSC Secretome to MSC Co-culture on Cardiomyocyte Gene Expression Under Hypoxic Conditions in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 502213.	4.1	5
9	Quantitative Hybrid Cardiac [18F]FDG-PET-MRI Images for Assessment of Cardiac Repair by Preconditioned Cardiosphere-Derived Cells. Molecular Therapy - Methods and Clinical Development, 2020, 18, 354-366.	4.1	9
10	Early Elevation of Systemic Plasma Clusterin after Reperfused Acute Myocardial Infarction in a Preclinical Porcine Model of Ischemic Heart Disease. International Journal of Molecular Sciences, 2020, 21, 4591.	4.1	4
11	Preclinical development of a miR-132 inhibitor for heart failure treatment. Nature Communications, 2020, 11, 633.	12.8	123
12	Reduced histologic neo in-stent restenosis after use of a paclitaxel-coated cutting balloon in porcine coronary arteries. Histology and Histopathology, 2020, 35, 653-663.	0.7	0
13	MiR-21, MiR-29a, GATA4, and MEF2c Expression Changes in Endothelin-1 and Angiotensin II Cardiac Hypertrophy Stimulated Isl-1+Sca-1+c-kit+ Porcine Cardiac Progenitor Cells In Vitro. Cells, 2019, 8, 1416.	4.1	9
14	Large Animal Models of Heart Failure With Reduced Ejection Fraction (HFrEF). Frontiers in Cardiovascular Medicine, 2019, 6, 117.	2.4	35
15	Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection. International Journal of Molecular Sciences, 2019, 20, 344.	4.1	10
16	Effect of Ischemic Preconditioning and Postconditioning on Exosome-Rich Fraction microRNA Levels, in Relation with Electrophysiological Parameters and Ventricular Arrhythmia in Experimental Closed-Chest Reperfused Myocardial Infarction. International Journal of Molecular Sciences, 2019, 20, 2140.	4.1	28
17	Targeted delivery and endosomal cellular uptake of DARPin-siRNA bioconjugates: Influence of linker stability on gene silencing. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 37-50.	4.3	10
18	Covalent Fluorophore Labeling of Oligonucleotides and Generation of Other Oligonucleotide Bioconjugates. Methods in Molecular Biology, 2019, 1943, 61-72.	0.9	0

#	Article	IF	Citations
19	Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles. International Journal of Pharmaceutics, 2018, 548, 793-802.	5.2	7
20	Preclinical Studies of Stem Cell Therapy for Heart Disease. Circulation Research, 2018, 122, 1006-1020.	4.5	104
21	Matrix Metalloproteinase-2 Impairs Homing of Intracoronary Delivered Mesenchymal Stem Cells in a Porcine Reperfused Myocardial Infarction: Comparison With Intramyocardial Cell Delivery. Frontiers in Bioengineering and Biotechnology, 2018, 6, 35.	4.1	14
22	Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins. Nucleic Acid Therapeutics, 2018, 28, 137-145.	3.6	4
23	Fluorescence- and computed tomography for assessing the biodistribution of siRNA after intratracheal application in mice. International Journal of Pharmaceutics, 2017, 525, 359-366.	5.2	12
24	Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Scientific Reports, 2017, 7, 43958.	3.3	33
25	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	7.1	280
26	Long-term regulation of gene expression in muscle cells by systemically delivered siRNA. Journal of Controlled Release, 2017, 256, 101-113.	9.9	6
27	Isolation of eudesmanes from Pluchea odorata and evaluation of their effects on cancer cell growth and tumor invasiveness inÂvitro. Phytochemistry, 2017, 141, 37-47.	2.9	4
28	RNAi-Mediated Knockdown of Protein Expression. Methods in Molecular Biology, 2017, 1654, 351-360.	0.9	2
29	Cardiac Stem Cell-based Regenerative Therapy for the Ischemic Injured Heart â€" a Short Update 2017. Journal of Cardiovascular Emergencies, 2017, 3, 81-83.	0.2	3
30	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	2.2	133
31	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. Journal of Translational Medicine, 2017, 15, 202.	4.4	33
32	Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget, 2017, 8, 67227-67240.	1.8	5
33	Molecular Imaging of Angiogenesis in Cardiac Regeneration. Current Cardiovascular Imaging Reports, 2016, 9, 27.	0.6	17
34	Fragment-based solid-phase assembly of oligonucleotide conjugates with peptide and polyethylene glycol ligands. European Journal of Medicinal Chemistry, 2016, 121, 132-142.	5.5	9
35	Triterpenoic Acids from Apple Pomace Enhance the Activity of the Endothelial Nitric Oxide Synthase (eNOS). Journal of Agricultural and Food Chemistry, 2016, 64, 185-194.	5.2	21
36	Inhibition of CD34+ cell migration by matrix metalloproteinase-2 during acute myocardial ischemia, counteracted by ischemic preconditioning. F1000Research, 2016, 5, 2739.	1.6	6

#	Article	IF	Citations
37	Inhibition of CD34+ cell migration by matrix metalloproteinase-2 during acute myocardial ischemia, counteracted by ischemic preconditioning. F1000Research, 2016, 5, 2739.	1.6	4
38	Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. Journal of Controlled Release, 2015, 203, 1-15.	9.9	240
39	Therapeutic oligonucleotides with polyethylene glycol modifications. Future Medicinal Chemistry, 2015, 7, 1721-1731.	2.3	24
40	Concise postsynthetic preparation of oligonucleotideâ€“oligopeptide conjugates through facile disulfide bond formation. Future Medicinal Chemistry, 2015, 7, 1657-1673.	2.3	10
41	Oligonucleotides conjugated with short chemically defined polyethylene glycol chains are efficient antisense agents. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5758-5761.	2.2	25
42	miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Medicinal Chemistry, 2014, 6, 1967-1984.	2.3	229
43	Chemically defined polyethylene glycol siRNA conjugates with enhanced gene silencing effect. Bioorganic and Medicinal Chemistry, 2014, 22, 2320-2326.	3.0	28
44	Secundarellone A, B, and C from the leaves of Justicia secunda VAHL. Phytochemistry Letters, 2014, 10, cxxix-cxxxii.	1.2	7
45	Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opinion on Biological Therapy, 2013, 13, 875-888.	3.1	97
46	Oligonucleotide conjugates for therapeutic applications. Therapeutic Delivery, 2013, 4, 791-809.	2.2	117
47	Characterization of Glucocerebrosides and the Active Metabolite 4,8-Sphingadienine from Arisaema amurense and Pinellia ternata by NMR and CD Spectroscopy and ESI-MS/CID-MS. Journal of Agricultural and Food Chemistry, 2012, 60, 7204-7210.	5.2	13
48	Off-Target Effects and Safety Aspects of Phosphorothioate Oligonucleotides. RNA Technologies, 2012, , 67-83.	0.3	8
49	Effects of NMDA receptor modulators on a bloodâ€“brain barrier in vitro model. Brain Research, 2011, 1394, 49-61.	2.2	48
50	Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides. Therapeutic Delivery, 2011, 2, 891-905.	2.2	28
51	2â€²-O-Lysylaminohexyladenosine modified oligonucleotides. Monatshefte FÃ¼r Chemie, 2010, 141, 809-815.	1.8	3
52	Offâ€Target Effects Related to the Phosphorothioate Modification of Nucleic Acids. ChemMedChem, 2010, 5, 1344-1352.	3.2	73
53	Bloodâ€“brain barrier cell line PBMEC/C1-2 possesses functionally active P-glycoprotein. Neuroscience Letters, 2010, 469, 224-228.	2.1	19
54	EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Molecular Cancer Therapeutics, 2009, 8, 2674-2683.	4.1	85

#	Article	IF	Citations
55	A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. Journal of Proteomics, 2009, 72, 1019-1030.	2.4	28
56	Oligonucleotideâ€“polyamine conjugates: Influence of length and position of 2â€²-attached polyamines on duplex stability and antisense effect. European Journal of Medicinal Chemistry, 2009, 44, 670-677.	5.5	31
57	2â€²â€‹Oâ€‹Lysylaminohexyl Oligonucleotides: Modifications for Antisense and siRNA. ChemMedChem, 2008, 3, 102-110.	3.2	27
58	Oligonucleotide Charge Reversal: 2â€²-O-Lysylaminohexyl Modified Oligonucleotides. Nucleosides, Nucleotides and Nucleic Acids, 2007, 26, 939-942.	1.1	4
59	Zwitterionic Oligonucleotides: A Study on Binding Properties of 2â€²-O-Aminohexyl Modifications. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1167-1185.	1.1	19
60	Oligonucleotides Conjugated to Short Lysine Chains. Bioconjugate Chemistry, 2005, 16, 1038-1044.	3.6	20
61	?-Methyl-2-amino-2,3-didesoxyribofuranoside, a Novel Building Block for Backbone Modified Antisense Oligonucleotides. Monatshefte FÃ¼r Chemie, 2004, 135, 109-116.	1.8	4
62	A novel concept for ligand attachment to oligonucleotides via a 2'-succinyl linker. Nucleic Acids Research, 2004, 32, 710-718.	14.5	21